VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice

被引:93
|
作者
Enterlein, S
Warfield, KL
Swenson, DL
Stein, DA
Smith, JL
Gamble, CS
Kroeker, AD
Iversen, PL
Bavari, S
Mühlberger, E
机构
[1] Univ Marburg, Dept Virol, D-35043 Marburg, Germany
[2] USA, Med Res Inst Infect Dis, Frederick, MD 21702 USA
[3] AVI BioPharma Inc, Corvallis, OR USA
关键词
D O I
10.1128/AAC.50.3.984-993.2006
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates.
引用
收藏
页码:984 / 993
页数:10
相关论文
共 50 条
  • [21] Ebola virus VP35 has novel NTPase and helicase-like activities
    Shu, Ting
    Gan, Tianyu
    Bai, Peng
    Wang, Xiaotong
    Qian, Qi
    Zhou, Hui
    Cheng, Qi
    Qiu, Yang
    Yin, Lei
    Zhong, Jin
    Zhou, Xi
    NUCLEIC ACIDS RESEARCH, 2019, 47 (11) : 5837 - 5851
  • [22] Structural and Functional Characterization of Reston Ebola Virus VP35 Interferon Inhibitory Domain
    Leung, Daisy W.
    Shabman, Reed S.
    Farahbakhsh, Mina
    Prins, Kathleen C.
    Borek, Dominika M.
    Wang, Tianjiao
    Muehlberger, Elke
    Basler, Christopher F.
    Amarasinghe, Gaya K.
    JOURNAL OF MOLECULAR BIOLOGY, 2010, 399 (03) : 347 - 357
  • [23] Identification of potential inhibitors targeting Ebola virus VP35 protein: a computational strategy
    Chen, Yan-kun
    Gahtani, Reem M.
    Al Shahrani, Mesfer
    Hani, Umme
    Alshabrmi, Fahad M.
    Alam, Sarfaraz
    Almohaimeed, Hailah M.
    Basabrain, Ammar A.
    Shahab, Muhammad
    Xie, Meng-zhou
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2025, 43 (06): : 2877 - 2889
  • [24] Ubiquitination of Ebola virus VP35 at lysine 309 regulates viral transcription and assembly
    van Tol, Sarah
    Kalveram, Birte
    Ilinykh, Philipp A.
    Ronk, Adam
    Huang, Kai
    Aguilera-Aguirre, Leopoldo
    Bharaj, Preeti
    Hage, Adam
    Atkins, Colm
    Giraldo, Maria, I
    Wakamiya, Maki
    Gonzalez-Orozco, Maria
    Warren, Abbey N.
    Bukreyev, Alexander
    Freiberg, Alexander N.
    Rajsbaum, Ricardo
    PLOS PATHOGENS, 2022, 18 (05)
  • [25] The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection
    Woolsey, Courtney
    Cross, Robert W.
    Chu, Victor C.
    Prasad, Abhishek N.
    Agans, Krystle N.
    Borisevich, Viktoriya
    Deer, Daniel J.
    Harrison, Mack B.
    Martinez, Jasmine K.
    Dobias, Natalie S.
    Fenton, Karla A.
    Cihlar, Tomas
    Nguyen, Anh-Quan
    Babusis, Darius
    Bannister, Roy
    Vermillion, Meghan S.
    Geisbert, Thomas W.
    SCIENCE ADVANCES, 2025, 11 (11):
  • [26] Ebola virus proteins NP, VP35, and VP24 are essential and sufficient to mediate nucleocapsid transport
    Takamatsu, Yuki
    Kolesnikova, Larissa
    Becker, Stephan
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (05) : 1075 - 1080
  • [27] Functional Importance of Hydrophobic Patches on the Ebola Virus VP35 IFN-Inhibitory Domain
    Kasajima, Nodoka
    Matsuno, Keita
    Miyamoto, Hiroko
    Kajihara, Masahiro
    Igarashi, Manabu
    Takada, Ayato
    VIRUSES-BASEL, 2021, 13 (11):
  • [28] Ebola virus VP35 perturbs type I interferon signaling to facilitate viral replication
    Cao, Zengguo
    Liu, Chenchen
    Peng, Cheng
    Ran, Yong
    Yao, Yulin
    Xiao, Gengfu
    Li, Entao
    Chen, Zixi
    Chuai, Xia
    Chiu, Sandra
    VIROLOGICA SINICA, 2023, 38 (06) : 922 - 930
  • [29] DRBP76 Associates With Ebola Virus VP35 and Suppresses Viral Polymerase Function
    Shabman, Reed S.
    Leung, Daisy W.
    Johnson, Joshua
    Glennon, Nicole
    Gulcicek, Erol E.
    Stone, Kathryn L.
    Leung, Lawrence
    Hensley, Lisa
    Amarasinghe, Gaya K.
    Basler, Christopher F.
    JOURNAL OF INFECTIOUS DISEASES, 2011, 204 : S911 - S918
  • [30] Identification of potential inhibitor against Ebola virus VP35: insight into virtual screening, pharmacoinformatics profiling, and molecular dynamic studies
    Ratul Bhowmik
    Ajay Manaithiya
    Bharti Vyas
    Ranajit Nath
    Sara Rehman
    Shubham Roy
    Ratna Roy
    Structural Chemistry, 2022, 33 : 815 - 831